SEC Form 4 · accession 0001562180-17-000141
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phil Gutry
Director
Period of report
Dec 31, 2016
Accepted (ET)
Jan 4, 2017 · 2:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.88 | Dec 31, 2016 | A | 3,793 | A | Dec 31, 2016 | Dec 30, 2026 | Common Stock | 3,793 | 3,793 | D |
Explanation of responses
- F1The stock options immediately vested and became exercisable in full upon grant on December 31, 2016.